[go: up one dir, main page]

WO2024086298A3 - Hla class i and class ii-restricted t-cell epitopes in pancreatic cancer tissues and uses thereof - Google Patents

Hla class i and class ii-restricted t-cell epitopes in pancreatic cancer tissues and uses thereof Download PDF

Info

Publication number
WO2024086298A3
WO2024086298A3 PCT/US2023/035535 US2023035535W WO2024086298A3 WO 2024086298 A3 WO2024086298 A3 WO 2024086298A3 US 2023035535 W US2023035535 W US 2023035535W WO 2024086298 A3 WO2024086298 A3 WO 2024086298A3
Authority
WO
WIPO (PCT)
Prior art keywords
class
restricted
pancreatic cancer
hla
cell epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/035535
Other languages
French (fr)
Other versions
WO2024086298A2 (en
Inventor
Lei Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of WO2024086298A2 publication Critical patent/WO2024086298A2/en
Publication of WO2024086298A3 publication Critical patent/WO2024086298A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein are HLA-class I and HLA-class II restricted and non-restricted epitopes recurrently identified in patients with cancer, that can be presented to T cell receptor (TCR) to induce polyfunctional T cell response, polyepitopes peptides thereof, vaccines thereof, and T cells having a TCR having a binding affinity for the epitopes and polyepitopes peptides, and methods of use thereof. The methods of use include methods of treating cancer.
PCT/US2023/035535 2022-10-20 2023-10-19 Hla class i and class ii-restricted t-cell epitopes in pancreatic cancer tissues and uses thereof Ceased WO2024086298A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263417951P 2022-10-20 2022-10-20
US63/417,951 2022-10-20

Publications (2)

Publication Number Publication Date
WO2024086298A2 WO2024086298A2 (en) 2024-04-25
WO2024086298A3 true WO2024086298A3 (en) 2024-06-27

Family

ID=90738390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/035535 Ceased WO2024086298A2 (en) 2022-10-20 2023-10-19 Hla class i and class ii-restricted t-cell epitopes in pancreatic cancer tissues and uses thereof

Country Status (1)

Country Link
WO (1) WO2024086298A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160166666A1 (en) * 2013-07-12 2016-06-16 Sumitomo Dainippon Pharma Co., Ltd. Tumor antigen peptide
US20200325174A1 (en) * 2014-06-20 2020-10-15 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
US20220128563A1 (en) * 2013-03-13 2022-04-28 Creatics Llc Methods and compositions for detecting pancreatic cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220128563A1 (en) * 2013-03-13 2022-04-28 Creatics Llc Methods and compositions for detecting pancreatic cancer
US20160166666A1 (en) * 2013-07-12 2016-06-16 Sumitomo Dainippon Pharma Co., Ltd. Tumor antigen peptide
US20200325174A1 (en) * 2014-06-20 2020-10-15 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)

Also Published As

Publication number Publication date
WO2024086298A2 (en) 2024-04-25

Similar Documents

Publication Publication Date Title
EP4461743A3 (en) T cell modification
AR119683A1 (en) ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO ORPHAN RECEPTOR TYROSINE KINASE-LIKE 1 (ROR1)
WO2007035843A3 (en) Methods and compositions for organ and tissue functionality
BRPI0618486A2 (en) multipotent progenitor cell use in adults
JP2018512047A5 (en)
Stamatopoulos et al. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
CY1122390T1 (en) METHODS OF USING IL-21 FOR ADAPTIVE IMMUNOTHERAPY AND IDENTIFICATION OF CANCER ANTIGONS
DE602006017556D1 (en) GENERATION OF ALLORESTRICTIVE SPECIFIC T CELLS
WO2013036795A3 (en) Oncolytic herpes simplex virus and therapeutic uses thereof
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
WO2009110940A3 (en) Virus-, bacteria-, and fungi-interacting layered phyllosilicates and methods of use
WO2023122206A3 (en) Multifuntional molecules binding to tcr and uses thereof
CY1111769T1 (en) CELL PREPARATION
WO2003012060A3 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
GB2641599A (en) Multifunctional molecules binding to TCR and uses thereof
WO2024254611A3 (en) Multispecific molecules binding to tcr and uses thereof
WO2024086298A3 (en) Hla class i and class ii-restricted t-cell epitopes in pancreatic cancer tissues and uses thereof
EP4148123A4 (en) In-vitro culture, induction, activation and cryopreservation method and cell bank establishment for immune cells
BR112021018100A2 (en) Methods for the differentiation and expansion of t lymphocytes and nk cells, for ex vivo enrichment and expansion of lymphocytes and for treating cancer, use of the method, cells, and cell composition
WO2009037439A3 (en) Methods of switching the phenotype of t cells by transgenic lineage factor foxp3
CA2866697A1 (en) Reprogramming of aged adult stem cells
WO2007047894A3 (en) Totipotent, nearly totipotent or pluripotent mammalian cells homozygous or hemizygous for one or more histocompatibility antigen genes
WO2020033555A3 (en) Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells
MX2024001208A (en) GENETICALLY MODIFIED PRIMARY CELLS FOR ALLOGENIC CELL THERAPY.
WO2018211509A3 (en) Selection and use of umbilical cord cell fractions suitable for transplantation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23880576

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23880576

Country of ref document: EP

Kind code of ref document: A2